Selective Reduction of Cysteine Residues in IL-17 Antibodies
Summary
The European Patent Office published patent application EP3237445A1 by Novartis AG, covering methods for the selective reduction of cysteine residues in IL-17 antibodies. The application names HEITZMANN, Markus and WINKLER, Johann as inventors, with international patent classification codes C07K 16/24 and A61K 39/395. This A1 publication includes the European search report and designates all EU member states plus Switzerland, Norway, and other European Economic Area countries.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 49 changes logged to date.
What changed
The EPO published patent application EP3237445A1 covering methods for selective reduction of cysteine residues in IL-17 antibodies. The application was filed by Novartis AG with inventors HEITZMANN, Markus and WINKLER, Johann. This A1 publication makes the technical disclosure publicly available and initiates the formal examination period. Competitors developing similar antibody modification technologies should review this filing for potential overlap with their own IP positions.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES
Publication EP3237445A1 Kind: A1 Apr 15, 2026
Applicants
Novartis AG
Inventors
HEITZMANN, Markus, WINKLER, Johann
IPC Classifications
C07K 16/24 20060101AFI20160704BHEP A61K 39/395 20060101ALI20160704BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.